Proligo and RNAx GmbH Announce Collaboration in the Area of RNAi

27-Apr-2004

Paris and Berlin, April 26, 2004 - Proligo (CO, USA) and RNAx announced the signing of a collaboration agreement in the area of RNAi. Under the terms of the agreement, RNAx provides Proligo with access to RNA interference functional validation technology (RNAi). Proligo will employ this technology for the functional validation of proprietary siRNA technologies. Proligo will own the derived results.

The collaboration is based on a technology platform developed by RNAx that validates siRNA oligos and gene targets for experimental and therapeutic use. Supported by automation technology, RNAi is employed to specifically inhibit gene expression. "We are glad to be able to provide our automated gene knockdown technology to Proligo. Although much work has already been done to improve functionality of siRNA oligos, validation still remains a key issue in the gene knockdown process. Our automated approach helps solve this problem at high speed, in a reliable way and will further improve the use of RNAi technology for specific applications." commented Joerg Poetzsch, Chief Executive Officer of RNAx.

Bruno Poddevin, Proligo Vice President Primers & Probes commented: "Using RNAx's RNAi technology, we anticipate that we will be able to dramatically improve the current synthetic siRNA silencing hit rate: only a single siRNA will be required to silence a gene. This will be a remarkable innovation for our industry, allowing large screening projects to become more affordable. We are very excited by this collaboration with RNAx. Their professionalism will allow us to move much faster on bringing new products to market."

https://www.bionity.com/en/news/36966/proligo-and-rnax-gmbh-announce-collaboration-in-the-area-of-rnai.html